Francesco De Rubertis, Medicxi co-founder
July 27, 2023 03:00 AM EDTUpdated 04:03 AM
Financing
Startups
Bioregnum

The vet­er­an crew at Medicxi is back with a new $400M fund and an up­beat as­sess­ment of what's com­ing

No two biotech VC groups are ex­act­ly the same.

Each has its own spe­cial­ty; each has its ideas about as­sets and plat­forms. And you can …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

A service from the Financial Times